A citation-based method for searching scientific literature

Jeffrey M Witkin, Anna E Martin, Lalit K Golani, Nina Z Xu, Jodi L Smith. Adv Pharmacol 2019
Times Cited: 28







List of co-cited articles
303 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
53

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
46

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
42

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Lace M Riggs, Jaclyn N Highland, Polymnia Georgiou, Edna F R Pereira, Edson X Albuquerque, Craig J Thomas, Carlos A Zarate,[...]. Pharmacol Rev 2018
408
32


A role for AMPA receptors in mood disorders.
Andrew Alt, Eric S Nisenbaum, David Bleakman, Jeffrey M Witkin. Biochem Pharmacol 2006
160
25

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Sungho Maeng, Carlos A Zarate, Jing Du, Robert J Schloesser, Joseph McCammon, Guang Chen, Husseini K Manji. Biol Psychiatry 2008
839
25

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
860
25

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
A John Rush, Madhukar H Trivedi, Stephen R Wisniewski, Andrew A Nierenberg, Jonathan W Stewart, Diane Warden, George Niederehe, Michael E Thase, Philip W Lavori, Barry D Lebowitz,[...]. Am J Psychiatry 2006
25

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
21

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
Panos Zanos, Jaclyn N Highland, Brent W Stewart, Polymnia Georgiou, Carleigh E Jenne, Jacqueline Lovett, Patrick J Morris, Craig J Thomas, Ruin Moaddel, Carlos A Zarate,[...]. Proc Natl Acad Sci U S A 2019
73
21

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
Todd D Gould, Carlos A Zarate, Scott M Thompson. Annu Rev Pharmacol Toxicol 2019
63
21




Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine.
Chao Dong, Ji-Chun Zhang, Wei Yao, Qian Ren, Min Ma, Chun Yang, Shigeyuki Chaki, Kenji Hashimoto. Int J Neuropsychopharmacol 2017
85
17

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Ronald S Duman, George K Aghajanian, Gerard Sanacora, John H Krystal. Nat Med 2016
742
17

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.
Ji-Chun Zhang, Su-Xia Li, Kenji Hashimoto. Pharmacol Biochem Behav 2014
197
17


R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto. Transl Psychiatry 2015
332
17



Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
17



Mechanisms of ketamine action as an antidepressant.
P Zanos, T D Gould. Mol Psychiatry 2018
361
14


Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.
Anna E Martin, Douglas A Schober, Alexander Nikolayev, Vladimir V Tolstikov, Wesley H Anderson, Richard E Higgs, Ming-Shang Kuo, Anastasia Laksmanan, John T Catlow, Xia Li,[...]. CNS Neurol Disord Drug Targets 2017
18
22

Sex Differences in the Temporal Neuromolecular and Synaptogenic Effects of the Rapid-acting Antidepressant Drug Ketamine in the Mouse Brain.
Connor Thelen, Emily Flaherty, Joseph Saurine, Jonathon Sens, Sara Mohamed, Pothitos M Pitychoutis. Neuroscience 2019
24
16

Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.
Eric S Wohleb, Danielle Gerhard, Alex Thomas, Ronald S Duman. Curr Neuropharmacol 2017
93
14


Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.
Chun Yang, Qian Ren, Youge Qu, Ji-Chun Zhang, Min Ma, Chao Dong, Kenji Hashimoto. Biol Psychiatry 2018
133
14

A neurotrophic model for stress-related mood disorders.
Ronald S Duman, Lisa M Monteggia. Biol Psychiatry 2006
14

An update on ketamine and its two enantiomers as rapid-acting antidepressants.
Kai Zhang, Kenji Hashimoto. Expert Rev Neurother 2019
64
14


Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Lijia Chang, Kai Zhang, Yaoyu Pu, Youge Qu, Si-Ming Wang, Zhongwei Xiong, Qian Ren, Chao Dong, Yuko Fujita, Kenji Hashimoto. Pharmacol Biochem Behav 2019
74
14

Taming the ketamine tiger. 1965.
Edward F Domino. Anesthesiology 2010
266
14


Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys.
Kenji Hashimoto, Takeharu Kakiuchi, Hiroyuki Ohba, Shingo Nishiyama, Hideo Tsukada. Eur Arch Psychiatry Clin Neurosci 2017
83
14

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.
Nanxin Li, Rong-Jian Liu, Jason M Dwyer, Mounira Banasr, Boyoung Lee, Hyeon Son, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Biol Psychiatry 2011
746
14

Ketamine abuse potential and use disorder.
Yu Liu, Deyong Lin, Boliang Wu, Wenhua Zhou. Brain Res Bull 2016
92
14

Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors.
Andrea Navarria, Eric S Wohleb, Bhavya Voleti, Kristie T Ota, Sophie Dutheil, Ashley E Lepack, Jason M Dwyer, Manabu Fuchikami, Astrid Becker, Filippo Drago,[...]. Neurobiol Dis 2015
80
14

M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.
J M Witkin, C Overshiner, X Li, J T Catlow, G N Wishart, D A Schober, B A Heinz, A Nikolayev, V V Tolstikov, W H Anderson,[...]. J Pharmacol Exp Ther 2014
72
14

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.
Martin M Katz, Janet L Tekell, Charles L Bowden, Steve Brannan, John P Houston, Nancy Berman, Alan Frazer. Neuropsychopharmacology 2004
192
14

Glutamate-based antidepressants: 20 years on.
Phil Skolnick, Piotr Popik, Ramon Trullas. Trends Pharmacol Sci 2009
301
14

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
Níall Lally, Allison C Nugent, David A Luckenbaugh, Mark J Niciu, Jonathan P Roiser, Carlos A Zarate. J Psychopharmacol 2015
118
14

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Nolan R Williams, Boris D Heifets, Christine Blasey, Keith Sudheimer, Jaspreet Pannu, Heather Pankow, Jessica Hawkins, Justin Birnbaum, David M Lyons, Carolyn I Rodriguez,[...]. Am J Psychiatry 2018
221
14

Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Yan Yang, Yihui Cui, Kangning Sang, Yiyan Dong, Zheyi Ni, Shuangshuang Ma, Hailan Hu. Nature 2018
390
14

Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Gustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, Manuela Telles, Rodrigo P Mello, Flavia Vieira, Cassio S Lima, Ana Paula Jesus-Nunes, Lívia N F Guerreiro-Costa, Roberta F Marback,[...]. Eur Arch Psychiatry Clin Neurosci 2021
100
14

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.
Eric W Lumsden, Timothy A Troppoli, Scott J Myers, Panos Zanos, Yasco Aracava, Jan Kehr, Jacqueline Lovett, Sukhan Kim, Fu-Hua Wang, Staffan Schmidt,[...]. Proc Natl Acad Sci U S A 2019
78
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.